Ravoxertinib benzenesulfonate

(Synonyms: GDC-0994 benzenesulfonate)
48 Cited Publications
Customer Review

Based on 48 publication(s) in Google Scholar

Ravoxertinib benzenesulfonate (GDC-0994 benzenesulfonate) is an orally active ERK1/2 inhibitor. Ravoxertinib benzenesulfonate inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib benzenesulfonate decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib benzenesulfonate can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.

For research use only. We do not sell to patients.

  • CAS No.: 1817728-45-2
  • Formula: C27H24ClFN6O5S
  • Molecular Weight:599.03
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Ravoxertinib benzenesulfonate

More
Customer Validation & Images
RT-PCRCell Proliferation/Viability AssayIP
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • RT-PCR
  • IP
  • RT-PCR
  • RT-PCR

All ERK Isoforms

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00